Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction).Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [213]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [178]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
(2000) · PubMed · Cited by 2,095
Research works printed but not linked: 2
- Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A
- 2002, Diabetic nephropathy, Diabetes Care, 25, S85
Cited by
Items 201–300 of 1,001
Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
Sowers, J. R., & Haffner, S. M. (2002) · Hypertension · doi:10.1161/01.hyp.0000042097.39655.b7 · Cited by 113
Carr, A. A., Kowey, P. R., Devereux, R. B., Brenner, B. M., Dahlöf, B., Ibsen, H., Lindholm, L. H., Lyle, P. A., Snapinn, S. M., Zhang, Z., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.061 · Cited by 117
Self-citationOmapatrilat—the story of Overture and Octave
Coats, A. J. S. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00389-3 · Cited by 107
Trespalacios, F. C., Taylor, A. J., Agodoa, L. Y. C., & Abbott, K. C. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00638.x · Cited by 112
Bushnell, C., Culebras, A., DeGraba, T. J., Goldstein, B. A., Adams, R. J., Alberts, M. J., & Appel, L. J. (2006) · Cited by 108
Diabetic Nephropathy: The Proteinuria Hypothesis
Williams, M. E. (2005) · American Journal of Nephrology · doi:10.1159/000084286 · Cited by 117
Haller, H. G., Viberti, G. C., Mimran, A., Remuzzi, G., Rabelink, T. J., Ritz, E., Rump, L. C., Ruilope, L. M., Katayama, S., Ito, S., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000202820.56201.e6 · Cited by 106
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
Copland, E., Canoy, D., Nazarzadeh, M., Bidel, Z., Ramakrishnan, R., Woodward, M., Chalmers, J., Teo, K. K., Pepine, C. J., Davis, B. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00033-4 · Cited by 103
Self-citationLow-grade albuminuria and cardiovascular risk: What is the evidence?
Schmieder, R. E., Schrader, J., Zidek, W., Tebbe, U., Paar, W. D., Bramlage, P., Pittrow, D., & Böhm, M. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0510-3 · Cited by 108
Uhlig, K., Levey, A. S., & Sarnak, M. J. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16028.x · Cited by 102
Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005
Marín, R., de la Sierra, Á., Armario, P., Campo, C., Banegas, J. R., & Gorostidi, M. (2005) · Medicina Clínica · doi:10.1157/13076402 · Cited by 152
Kizer, J. R., Dahlöf, B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristianson, K., Lederballe-Pedersen, O., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000151324.05355.1c · Cited by 101
Self-citationEvidence in Guidelines for Treatment of Coronary Artery Disease
Jia, S., Liu, Y., & Yuan, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_2 · Cited by 125
Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?
de Zeeuw, D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09201.x · Cited by 102
Sandbaek, A., Griffin, S. J., Rutten, G., Davies, M., Stolk, R., Khunti, K., Borch-Johnsen, K., Wareham, N. J., & Lauritzen, T. (2008) · Diabetologia · doi:10.1007/s00125-008-1013-0 · Cited by 97
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., Mbewu, A., & Opie, L. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub3 · Cited by 97
Sodium Intake Regulates Glucose Homeostasis through the PPARδ/Adiponectin-Mediated SGLT2 Pathway
Zhao, Y., Gao, P., Sun, F., Li, Q., Chen, J., Yu, H., Li, L., Wei, X., He, H., Lu, Z., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.019 · Cited by 104
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
Bernardi, S., Michelli, A., Zuolo, G., Candido, R., & Fabris, B. (2016) · Journal of Diabetes Research · doi:10.1155/2016/8917578 · Cited by 105
Fretheim, A., Odgaard-Jensen, J., Brørs, O., Madsen, S., Njølstad, I., Norheim, O. F., Svilaas, A., Kristiansen, I. S., Thürmer, H., & Flottorp, S. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-33 · Cited by 94
ACE2: A novel therapeutic target for cardiovascular diseases
Sarkissian, S. D., Huentelman, M. J., Stewart, J. M., Katovich, M. J., & Raizada, M. K. (2005) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2005.05.011 · Cited by 103
Treatment of Hypertension in Patients With Diabetes
Sowers, J. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.17.1850 · Cited by 101
Current Management Strategies for Coexisting Diabetes Mellitus and Obesity
Scheen, A. J. (2003) · Drugs · doi:10.2165/00003495-200363120-00001 · Cited by 110
Baker, D. W. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.0805333 · Cited by 110
Niklason, A., Hedner, T., Niskanen, L., & Lanke, J. (2004) · Journal of Hypertension · doi:10.1097/00004872-200403000-00029 · Cited by 89
Raebel, M. A., McClure, D. L., Simon, S. R., Chan, K. A., Feldstein, A., Andrade, S. E., Lafata, J. E., Roblin, D., Davis, R. L., Gunter, M. J., et al. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1217 · Cited by 89
Flammer, A. J., Hermann, F., Wiesli, P., Schwegler, B., Chenevard, R., Hürlimann, D., Sudano, I., Gay, S., Neidhart, M., Riesen, W., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280287a72 · Cited by 94
Kaiser, T., Heise, T., Nosek, L., Eckers, U., & Sawicki, P. T. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000234121.48272.67 · Cited by 89
Savoia, C., Touyz, R. M., Endemann, D. H., Pu, Q., Ko, E. A., De Ciuceis, C., & Schiffrin, E. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000230234.84356.36 · Cited by 89
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
Lindholm, L. H., Dahlöf, B., Edelman, J. M., Ibsen, H., Borch‐Johnsen, K., Olsen, M. H., Snapinn, S. M., & Wachtell, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14183-9 · Cited by 88
Self-citationNomura, S., Shouzu, A., Omoto, S., Nishikawa, M., & Iwasaka, T. (2004) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960401000203 · Cited by 87
Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
Patel, B. M., & Mehta, A. A. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.034 · Cited by 91
Treatment of metabolic syndrome
Wagh, A., & Stone, N. J. (2004) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2.2.213 · Cited by 100
Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With Diabetes
Winkelmayer, W. C., Fischer, M. A., Schneeweiß, S., Wang, P. S., Levin, R., & Avorn, J. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.018 · Cited by 91
Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
Ruilope, L. M., Rosei, E. A., Bakris, G. L., Mancia, G., Poulter, N. R., Taddei, S., Unger, T., Volpe, M., Waeber, B., & Zannad, F. M. (2005) · Blood Pressure · doi:10.1080/08037050500230227 · Cited by 95
Chen, Y. J., Li, L. J., Tang, W. L., Song, J. Y., Qiu, R., Li, Q., Xue, H., & Wright, J. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008170.pub3 · Cited by 99
Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy
de Zeeuw, D. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.002 · Cited by 89
Kjeldsen, S. E. (2004) · Heart Drug · doi:10.1159/000076263 · Cited by 84
Self-citationThe effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects
Nagel, J. M., Tietz, A. B., Göke, B., & Parhofer, K. G. (2006) · Metabolism · doi:10.1016/j.metabol.2006.04.011 · Cited by 91
Should Angiotensin II Receptor Blockers and Statins Be Combined?
Nickenig, G. (2004) · Circulation · doi:10.1161/01.cir.0000139857.85424.45 · Cited by 91
Goldenberg, R. M., Cheng, A. Y. Y., Fitzpatrick, T., Gilbert, J. D., Verma, S., & Hopyan, J. J. (2022) · Stroke · doi:10.1161/strokeaha.121.038151 · Cited by 82
Sharma, P., Blackburn, R. C., Parke, C. L., McCullough, K., Marks, A., & Black, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007751.pub2 · Cited by 83
Kovell, L. C., Ahmed, H. M., Misra, S., Whelton, S. P., Prokopowicz, G. P., Blumenthal, R. S., & McEvoy, J. W. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002315 · Cited by 82
Bloomgarden, Z. T. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1297 · Cited by 121
Gilbert, R. E., Krum, H., Wilkinson‐Berka, J. L., & Kelly, D. J. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00979.x · Cited by 105
Plutzky, J., Viberti, G. C., & Haffner, S. M. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00202-7 · Cited by 94
Hopes, disillusions and more hopes from vitamin C
Tullio, M. C. D., & Arrigoni, O. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3203-8 · Cited by 88
Cardiovascular Disease and Diabetes
Bloomgarden, Z. T. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.230 · Cited by 91
The role of angiotensin II in nonalcoholic steatohepatitis
Morris, E. M., Fletcher, J. A., Thyfault, J. P., & Rector, R. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.04.013 · Cited by 89
Chrysant, S. G., Marbury, T. C., & Robinson, T. D. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001577 · Cited by 86
Battisti, W. P., Palmisano, J. J., & Keane, W. F. (2003) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2003.181 · Cited by 96
Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus
DePaula, A. L., Macedo, A. L. V., Rassi, N., Vencio, S. A. C., Machado, C. A., Mota, B., Silva, L. Q., Halpern, A., & Schraibman, V. (2008) · Surgical Endoscopy · doi:10.1007/s00464-008-9808-0 · Cited by 86
Irbesartan: A Review of its Use in Hypertension and in the Management of Diabetic Nephropathy
Croom, K. F., Curran, M. P., Goa, K. L., & Perry, C. M. (2004) · Drugs · doi:10.2165/00003495-200464090-00011 · Cited by 90
Okin, P. M., Devereux, R. B., Gerdts, E., Snapinn, S. M., Harris, K. E., Jern, S., Kjeldsen, S. E., Julius, S., Edelman, J. M., Lindholm, L. H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.574822 · Cited by 87
Self-citationBriasoulis, A., Agarwal, V., Tousoulis, D., & Stefanadis, C. (2014) · Heart · doi:10.1136/heartjnl-2013-304111 · Cited by 78
Influence of body and arm position on blood pressure readings: an overview
Netea, R. T., Lenders, J. W. M., Smits, P., & Thien, T. A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200302000-00006 · Cited by 84
Understanding EMPA-REG OUTCOME
Muskiet, M. H. A., van Raalte, D. H., van Bommel, E. J. M., Smits, M. M., & Tonneijck, L. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00424-6 · Cited by 79
Meems, L. M. G., Cannon, M. V., Mahmud, H., Voors, A. A., van Gilst, W. H., Silljé, H. H. W., Ruifrok, W.-P. T., & de Boer, R. A. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.06.004 · Cited by 79
Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring
Raebel, M. A., Ross, C. A., Xu, S., Roblin, D. W., Cheetham, C., Blanchette, C. M., Saylor, G., & Smith, D. H. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1228-x · Cited by 79
Park, I. U., & Taylor, A. L. (2007) · The Annals of Family Medicine · doi:10.1370/afm.708 · Cited by 83
Watanabe, S., Tagawa, T., Yamakawa, K., Shimabukuro, M., & Ueda, S. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000187465.55507.85 · Cited by 75
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
The renin-angiotensin system and insulin resistance
Liu, Z. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0007-5 · Cited by 82
ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting
Bates, E., Babb, C. J. D., Casey, D. E., Cates, C. U., Duckwiler, G., Feldman, T. E., Gray, W. A., Ouriel, K., Peterson, E. D., Rosenfield, K., et al. (2007) · Vascular Medicine · doi:10.1177/1358863x06076103 · Cited by 79
Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH
Böhm, M., Reil, J., Danchin, N., Thoenes, M., Bramlage, P., & Volpe, M. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f05c8a · Cited by 80
Authors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 87
Mancia, G., Volpe, R., Boros, S., Ilardi, M., & Giannattasio, C. (2003) · Journal of Hypertension · doi:10.1097/00004872-200401000-00012 · Cited by 75
González‐Juanatey, J. R., Ramos, P. M., Arcos, F. S., Alonso, V. B., Padial, L. R., & Bertoméu, V. (2003) · Revista Española de Cardiología · doi:10.1016/s0300-8932(03)76904-8 · Cited by 103
The frail renin–angiotensin system
Abadir, P. M. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.08.004 · Cited by 70
Xue, H., Lu, Z., Tang, W. L., Pang, L. W., Wang, G. M., Wong, G. W., & Wright, J. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008170.pub2 · Cited by 70
Principles of Screening for Chronic Kidney Disease
Jaar, B. G., Khatib, R., Plantinga, L., Boulware, L. E., & Powe, N. R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02540607 · Cited by 81
Malacco, E., Santonastaso, M., Varì, N. A., Gargiulo, A., Spagnuolo, V., Bertocchi, F., Palatini, P., & PREVAIL Study Investigators (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90129-4 · Cited by 75
Coletta, A. P., Thackray, S. D. R., Nikitin, N. P., & Cleland, J. G. F. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(02)00040-5 · Cited by 76
Devereux, R. B., Dahlf, B., Kjeldsen, S. E., Julius, S., Aurup, P., Beevers, G., Edelman, J. M., de Faire, U., Fyhrquist, F., Berg, S. H., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00006 · Cited by 68
Self-citationObesity, Hypertension, and Insulin Resistance
Bloomgarden, Z. T. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2088 · Cited by 87
Kjeldsen, S. E. (2004) · Heart Drug · doi:10.1159/000076262 · Cited by 71
Self-citationAldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease
McFarlane, S. I., & Sowers, J. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021443 · Cited by 67
Matsumoto, S., Shimabukuro, M., Fukuda, D., Soeki, T., Yamakawa, K., Masuzaki, H., & Sata, M. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-30 · Cited by 74
Bahadır, Ö., Uzunlulu, M., Oğuz, A., & Bahadır, M. A. (2007) · Hypertension Research · doi:10.1291/hypres.30.49 · Cited by 67
Desai, C. S., Ning, H., & Lloyd‐Jones, D. M. (2011) · Heart · doi:10.1136/heartjnl-2011-300819 · Cited by 65
Otsuka, R., Tange, C., Nishita, Y., Kato, Y., Tomida, M., Imai, T., Ando, F., & Shimokata, H. (2020) · Nutrients · doi:10.3390/nu12041052 · Cited by 74
Calkin, A. C., Giunti, S., Sheehy, K., Chew, C., Boolell, V., Rajaram, Y. S., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2008) · Diabetologia · doi:10.1007/s00125-008-1060-6 · Cited by 68
Antihypertensive therapy and new onset diabetes
Messerli, F. H., Grossman, E., & Leonetti, G. (2004) · Journal of Hypertension · doi:10.1097/00004872-200410000-00001 · Cited by 66
Kjeldsen, S. E., & Julius, S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.037 · Cited by 65
Self-citationPrevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes
Srivastava, P., Calafiore, P. A., MacIsaac, R. J., Patel, S. K., Thomas, M. C., Jerums, G., & Burrell, L. M. (2008) · Clinical Science · doi:10.1042/cs20070261 · Cited by 63
Madison, J. R., Spies, C., Schatz, I. J., Masaki, K., Chen, R., Yano, K., & Curb, J. D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.8.884 · Cited by 67
Losartan and Simvastatin Inhibit Platelet Activation in Hypertensive Patients
Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M., Fukuhara, S., & Iwasaka, T. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-005-0343-8 · Cited by 66
Rayner, B. L., Trinder, Y. A., BAINES, D., Isaacs, S., & Opie, L. H. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.08.005 · Cited by 61
Williams, B., Poulter, N. R., Mj, B., Davis, M. R., & Sever, P. (2004) · Cited by 61
Hypertension‐Related Morbidity and Mortality in African Americans—Why We Need to Do Better
Ferdinand, K. C., & Sounders, E. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.05295.x · Cited by 65
Prediabetes: The Importance of Early Identification and Intervention
Hsueh, W. A., Orloski, L., & Wyne, K. L. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2180 · Cited by 71
Koulouris, S. N., Symeonides, P., Triantafyllou, K. A., Ioannidis, G., Karabinos, I. K., Katostaras, T., El-Ali, M., Theodoridis, T., Vratsista, E., Thalassinos, N., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.01.092 · Cited by 64
Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance
Henriksen, E. J., & Jacob, S. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00265.x · Cited by 63
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 59
Hypertension, left ventricular hypertrophy, and sudden death
Tin, L., Beevers, D. G., & Lip, G. Y. H. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0105-6 · Cited by 70
Preiss, D., Sattar, N. A., & McMurray, J. J. V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.10.019 · Cited by 63
Yasuda, N., Akazawa, H., Qin, Y., Zou, Y., & Komuro, I. (2007) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0215-1 · Cited by 63
Preventing Type II Diabetes Mellitus
Prisant, L. M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004263018 · Cited by 58
Safety of Telmisartan in Patients with Arterial Hypertension: An Open-Label Observational Study
Michel, M. C., Bohner, H., K??ster, J., fers, R. F. S., & Heemann, U. W. (2004) · Drug Safety · doi:10.2165/00002018-200427050-00005 · Cited by 68
Do angiotensin II receptor blockers increase the risk of myocardial infarction?
Verdecchia, P., Angeli, F., Gattobigio, R., & Reboldi, G. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi445 · Cited by 63
Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications
Peleli, M., & Carlström, M. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.12.001 · Cited by 63
Metadata
- Authors
- Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S.
- Affiliations
- University Hospital of Umeå (SE)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- University of Michigan (US)
- Oslo University Hospital (NO)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lindholm, Lars H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 1004-1010
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1982920623
- Cited by
- 1,560
- References
- 31
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 29 · 2019: 16 · 2018: 28 · 2017: 40 · 2016: 40 · 2015: 41 · 2014: 48 · 2013: 58 · 2012: 58
- FWCI
- 129.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- losartan, atenolol, hypertension, diabetes mellitus, left ventricular hypertrophy, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, ACE inhibitors, beta-blockers, LIFE trial, stroke, myocardial infarction, all-cause mortality, blood pressure reduction, Framingham risk score, electrocardiogram
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.